Cybin’s (CYBN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Cybin (NYSE:CYBN) in a research note published on Friday morning, Benzinga reports.

Separately, HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares of Cybin in a research note on Thursday, May 16th.

Cybin Stock Performance

CYBN stock opened at $0.26 on Friday. The company has a market capitalization of $108.34 million, a P/E ratio of -1.26 and a beta of 0.50. Cybin has a 1 year low of $0.25 and a 1 year high of $0.74.

Institutional Trading of Cybin

A number of hedge funds have recently bought and sold shares of CYBN. PEAK6 Investments LLC acquired a new stake in shares of Cybin during the first quarter worth $95,000. AWM Investment Company Inc. purchased a new position in Cybin during the first quarter worth about $930,000. Ikarian Capital LLC acquired a new stake in Cybin in the 1st quarter worth about $5,770,000. Finally, RA Capital Management L.P. purchased a new stake in Cybin in the 1st quarter valued at about $24,041,000. Institutional investors and hedge funds own 17.94% of the company’s stock.

About Cybin

Cybin Inc is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc is based in Toronto, Canada.